Do analysts recommend LIPO or JAGX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, LIPO or BPTSY?

Lipella Pharmaceuticals has higher revenue and earnings than Biophytis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipella Pharmaceuticals $536.36K 0.00 -$5.02M -$2.42 N/A Biophytis N/A N/A -$18.43M N/A N/A

Do analysts rate LIPO or SBFM?

Sunshine Biopharma has a consensus target price of $70.00, indicating a potential upside of 4,900.00%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Lipella Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend CERO or LIPO?

CERo Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 333,233.33%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than Lipella Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend LIPO or PTIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Lipella Pharmaceuticals (LIPO) Competitors

$0.0002 0.00 (0.00%)

As of 08/6/2026 01:01 PM Eastern

Compare

LIPO vs. JAGX, BPTSY, SBFM, CERO, and PTIX

Should you buy Lipella Pharmaceuticals stock or one of its competitors? MarketBeat compares Lipella Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lipella Pharmaceuticals include Jaguar Animal Health (JAGX), Biophytis (BPTSY), Sunshine Biopharma (SBFM), CERo Therapeutics (CERO), and Atrinsic (PTIX).

How does Lipella Pharmaceuticals compare to Jaguar Animal Health?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Jaguar Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jaguar Animal Health has a net margin of -169.04% compared to Lipella Pharmaceuticals' net margin of -988.83%. Jaguar Animal Health's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%
Jaguar Animal Health	-169.04%	N/A	-115.55%

Lipella Pharmaceuticals has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Jaguar Animal Health has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

In the previous week, Jaguar Animal Health had 2 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 2 mentions for Jaguar Animal Health and 0 mentions for Lipella Pharmaceuticals. Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Jaguar Animal Health'saverage media sentiment score.

Company	Overall Sentiment
Lipella Pharmaceuticals	Neutral
Jaguar Animal Health	Neutral

Lipella Pharmaceuticals has higher earnings, but lower revenue than Jaguar Animal Health. Jaguar Animal Health is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipella Pharmaceuticals	$536.36K	0.00	-$5.02M	-$2.42	N/A
Jaguar Animal Health	$11.51M	0.05	-$53.43M	-$591.92	N/A

Summary

Jaguar Animal Health beats Lipella Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Biophytis?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Biophytis has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Biophytis' return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%
Biophytis	N/A	N/A	N/A

Lipella Pharmaceuticals has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipella Pharmaceuticals	$536.36K	0.00	-$5.02M	-$2.42	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

In the previous week, Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Lipella Pharmaceuticals	Neutral
Biophytis	Neutral

Lipella Pharmaceuticals has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its stock price is 146% more volatile than the broader market.

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Lipella Pharmaceuticals and Biophytis tied by winning 4 of the 8 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Sunshine Biopharma?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Sunshine Biopharma has a net margin of -18.45% compared to Lipella Pharmaceuticals' net margin of -988.83%. Sunshine Biopharma's return on equity of -27.75% beat Lipella Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

Sunshine Biopharma has a consensus target price of $70.00, indicating a potential upside of 4,900.00%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Lipella Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lipella Pharmaceuticals has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

In the previous week, Sunshine Biopharma had 2 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 2 mentions for Sunshine Biopharma and 0 mentions for Lipella Pharmaceuticals. Sunshine Biopharma's average media sentiment score of 0.68 beat Lipella Pharmaceuticals' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Lipella Pharmaceuticals	Neutral
Sunshine Biopharma	Positive

Lipella Pharmaceuticals has higher earnings, but lower revenue than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipella Pharmaceuticals	$536.36K	0.00	-$5.02M	-$2.42	N/A
Sunshine Biopharma	$36.31M	0.02	-$5.97M	-$12.90	N/A

Summary

Sunshine Biopharma beats Lipella Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to CERo Therapeutics?

CERo Therapeutics (NASDAQ:CERO) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CERo Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 333,233.33%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than Lipella Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Lipella Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CERo Therapeutics	Neutral
Lipella Pharmaceuticals	Neutral

CERo Therapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. CERo Therapeutics' return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%

CERo Therapeutics has a beta of 0.13, indicating that its stock price is 87% less volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

Lipella Pharmaceuticals has higher revenue and earnings than CERo Therapeutics. CERo Therapeutics is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A
Lipella Pharmaceuticals	$536.36K	0.00	-$5.02M	-$2.42	N/A

Summary

Lipella Pharmaceuticals beats CERo Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Atrinsic?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Atrinsic (NASDAQ:PTIX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 8.0% of Atrinsic shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Comparatively, 8.0% of Atrinsic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Atrinsic had 1 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 1 mentions for Atrinsic and 0 mentions for Lipella Pharmaceuticals. Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Atrinsic'saverage media sentiment score.

Company	Overall Sentiment
Lipella Pharmaceuticals	Neutral
Atrinsic	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lipella Pharmaceuticals has higher revenue and earnings than Atrinsic. Atrinsic is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipella Pharmaceuticals	$536.36K	0.00	-$5.02M	-$2.42	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

Atrinsic has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Atrinsic's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%
Atrinsic	N/A	N/A	-379.72%

Lipella Pharmaceuticals has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Atrinsic has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Summary

Lipella Pharmaceuticals beats Atrinsic on 8 of the 12 factors compared between the two stocks.

Get Lipella Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIPO vs. The Competition

Export

Metric	Lipella Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1K	$3.61B	$6.95B	$12.87B
Dividend Yield	N/A	3.76%	2.59%	9.93%
P/E Ratio	0.00	8.36	271.13	25.30
Price / Sales	0.00	1,282.56	658.25	106.23
Price / Cash	N/A	101.37	71.89	50.37
Price / Book	0.00	17.65	13.03	6.13
Net Income	-$5.02M	-$13.22M	$3.46B	$342.95M
7 Day Performance	N/A	4.43%	3.41%	3.19%
1 Month Performance	N/A	-4.90%	-2.67%	-1.98%
1 Year Performance	N/A	56.56%	75.99%	21.11%

Lipella Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIPO Lipella Pharmaceuticals	N/A	$0.00 flat	N/A	-100.0%	$1K	$536.36K	N/A	4
JAGX Jaguar Animal Health	0.3865 of 5 stars	$0.98 +1.8%	N/A	-98.8%	$587K	$11.51M	N/A	50	News Coverage Upcoming Earnings Gap Up
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30
SBFM Sunshine Biopharma	3.0513 of 5 stars	$1.18 -4.5%	$70.00 +5,857.4%	-90.0%	$554K	$36.31M	N/A	3	Upcoming Earnings Gap Up
CERO CERo Therapeutics	N/A	$0.01 flat	$30.00 +299,900.0%	-99.9%	$451K	N/A	N/A	8	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIPO) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lipella Pharmaceuticals (LIPO) Competitors

LIPO vs. JAGX, BPTSY, SBFM, CERO, and PTIX

How does Lipella Pharmaceuticals compare to Jaguar Animal Health?

Summary

How does Lipella Pharmaceuticals compare to Biophytis?

Summary

How does Lipella Pharmaceuticals compare to Sunshine Biopharma?

Summary

How does Lipella Pharmaceuticals compare to CERo Therapeutics?

Summary

How does Lipella Pharmaceuticals compare to Atrinsic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIPO vs. The Competition

Lipella Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lipella Pharmaceuticals (LIPO) Competitors

LIPO vs. JAGX, BPTSY, SBFM, CERO, and PTIX

How does Lipella Pharmaceuticals compare to Jaguar Animal Health?

Do institutionals & insiders have more ownership in LIPO or JAGX?

Do analysts recommend LIPO or JAGX?

Is LIPO or JAGX more profitable?

Which has more volatility & risk, LIPO or JAGX?

Does the media prefer LIPO or JAGX?

Which has better valuation & earnings, LIPO or JAGX?

Summary

How does Lipella Pharmaceuticals compare to Biophytis?

Is LIPO or BPTSY more profitable?

Which has higher valuation & earnings, LIPO or BPTSY?

Does the media refer more to LIPO or BPTSY?

Which has more risk and volatility, LIPO or BPTSY?

Do institutionals & insiders believe in LIPO or BPTSY?

Summary

How does Lipella Pharmaceuticals compare to Sunshine Biopharma?

Is LIPO or SBFM more profitable?

Do analysts rate LIPO or SBFM?

Do institutionals and insiders believe in LIPO or SBFM?

Which has more volatility & risk, LIPO or SBFM?

Does the media favor LIPO or SBFM?

Which has better earnings and valuation, LIPO or SBFM?

Summary

How does Lipella Pharmaceuticals compare to CERo Therapeutics?

Do insiders and institutionals believe in CERO or LIPO?

Do analysts recommend CERO or LIPO?

Does the media favor CERO or LIPO?

Is CERO or LIPO more profitable?

Which has more volatility & risk, CERO or LIPO?

Which has preferable earnings & valuation, CERO or LIPO?

Summary

How does Lipella Pharmaceuticals compare to Atrinsic?

Do institutionals and insiders hold more shares of LIPO or PTIX?

Does the media favor LIPO or PTIX?

Do analysts recommend LIPO or PTIX?

Which has stronger valuation and earnings, LIPO or PTIX?

Is LIPO or PTIX more profitable?

Which has more volatility & risk, LIPO or PTIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIPO vs. The Competition

Lipella Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools